IMXQB-80: A Quillaja brasiliensis saponin-based nanoadjuvant enhances Zika virus specific immune responses in mice. 2021

Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
Centro de Biotecnologia - CBiotec, Laboratório de Biotecnologia Celular e Molecular, Universidade Federal da Paraíba, João Pessoa, Paraíba, Brazil; Departamento de Microbiologia Imunologia e Parasitologia, Laboratório de Virologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.

Vaccine adjuvants are compounds that enhance/prolong the immune response to a co-administered antigen. Saponins have been widely used as adjuvants for many years in several vaccines - especially for intracellular pathogens - including the recent and somewhat revolutionary malaria and shingles vaccines. In view of the immunoadjuvant potential of Q. brasiliensis saponins, the present study aimed to characterize the QB-80 saponin-rich fraction and a nanoadjuvant prepared with QB-80 and lipids (IMXQB-80). In addition, the performance of such adjuvants was examined in experimental inactivated vaccines against Zika virus (ZIKV). Analysis of QB-80 by DI-ESI-ToF by negative ion electrospray revealed over 29 saponins that could be assigned to known structures existing in their congener Q. saponaria, including the well-studied QS-21 and QS-7. The QB-80 saponins were a micrOTOF able to self-assembly with lipids in ISCOM-like nanoparticles with diameters of approximately 43 nm, here named IMXQB-80. Toxicity assays revealed that QB-80 saponins did present some haemolytical and cytotoxic potentials; however, these were abrogated in IMXQB-80 nanoparticles. Regarding the adjuvant activity, QB-80 and IMXQB-80 significantly enhanced serum levels of anti-Zika virus IgG and subtypes (IgG1, IgG2b, IgG2c) as well as neutralized antibodies when compared to an unadjuvanted vaccine. Furthermore, the nanoadjuvant IMXQB-80 was as effective as QB-80 in stimulating immune responses, yet requiring fourfold less saponins to induce the equivalent stimuli, and with less toxicity. These findings reveal that the saponin fraction QB-80, and particularly the IMXQB-80 nanoadjuvant, are safe and capable of potentializing immune responses when used as adjuvants in experimental ZIKV vaccines.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D000071243 Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME. Congenital Zika Syndrome,Congenital Zika Virus Infection,Fever, Zika,ZikV Infection,Zika Fever,Zika Virus Disease,Disease, Zika Virus,Infection, ZikV,Infection, Zika Virus,Virus Disease, Zika,Virus Infection, Zika
D000071244 Zika Virus An arbovirus in the FLAVIVIRUS genus of the family FLAVIVIRIDAE. Originally isolated in the Zika Forest of UGANDA it has been introduced to Asia and the Americas. Virus, Zika,ZikV
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012503 Saponins A type of glycoside widely distributed in plants. Each consists of a sapogenin as the aglycone moiety, and a sugar. The sapogenin may be a steroid or a triterpene and the sugar may be glucose, galactose, a pentose, or a methylpentose. Saponin
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D062605 Quillaja Saponins Natural detergents made up of a heterogeneous mixture of molecules having a triterpenoid core structure. They vary in aglycone (sapogenin) and sugar moieties, including glucose. Quillaja Saponin,Saponin, Quillaja,Saponins, Quillaja
D031990 Quillaja A plant genus of the family ROSACEAE whose members produce SAPONINS. Soapbark,Soapbush,Quillaja Saponaria,Quillaja Saponarias,Quillajas,Saponaria, Quillaja,Saponarias, Quillaja,Soapbarks,Soapbushs

Related Publications

Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
September 2018, Scientific reports,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
May 1986, Canadian journal of microbiology,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
September 1996, Vaccine,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
November 2006, Vaccine,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
January 2014, PloS one,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
January 2018, Vaccine,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
July 2017, Vaccine,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
January 2013, Natural product research,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
November 1995, Journal of pharmaceutical sciences,
Samuel Cibulski, and Thais Fumaco Teixeira, and Ana Paula Muterle Varela, and Matheus Fabião de Lima, and Gabriela Casanova, and Yuri Mangueira Nascimento, and Josean Fechine Tavares, and Marcelo Sobral da Silva, and Patrícia Sesterheim, and Diogo Onofre Souza, and Paulo Michel Roehe, and Fernando Silveira
February 2019, Journal of colloid and interface science,
Copied contents to your clipboard!